Median Technologies Announces Results of Deep Learning Study for Enhanced Prostate Segmentation – Helping to Advance Precis...
February 13 2018 - 11:45AM
Business Wire
Results to be presented at the SPIE Medical
Imaging conference in Houston, TX, USA
Regulatory News:
Median Technologies, the industry-leading Imaging Phenomics
Company® (Paris:ALMDT) announced today results of a deep learning
study for enhanced prostate segmentation. With more accurate
segmentation, new therapeutic decision-making tools can help
advance precision medicine. Study results will be presented at the
SPIE Medical Imaging conference in Houston, TX, USA on February
14.
The study, “Assessing the relevance of multi-planar MRI
acquisitions for prostate segmentation using deep learning
techniques,” relates to prostate cancer detection and presents
a deep learning-based method for prostate segmentation using
magnetic resonance images acquired in two imaging views. The
results were compared to manual tracings performed by medical image
analysts and were evaluated by the number of cancerous lesions
within the segmentation. The study shows the proposed method
performs better than methods relying on a single imaging view. This
highlights the possibilities for design of fully automatic,
accurate, fast and reproducible prostate segmentation computer
systems.
Deep learning, a field of artificial intelligence, enables
computer systems to improve analysis by using experience and data.
It has very promising applications in healthcare, particularly in
the medical imaging field to develop computer-aided systems for the
management of diseases such as cancer. A key step in developing
computer-aided systems for cancer detection is organ
segmentation.
The study will be presented during the poster session, “Machine
Learning and Artificial Intelligence,” to be held on Wednesday 14
February, from 5:30p to 7:00p CST.
Please visit SPIE Medical Imaging Conference, for more
information on the conference.
About Median Technologies: Median Technologies provides
innovative imaging solutions and services to advance healthcare for
everyone. We leverage the power of Imaging Phenomics to provide
insights into novel therapies and treatment strategies. Our unique
solutions, MediScan® for Patient Care, iSee® for image management
in clinical trials and iBiopsy® for imaging phenotyping, together
with our global team of experts, are advancing the development of
new drugs and diagnostic tools to monitor disease and assess
response to therapy. Median Technologies supports biopharmaceutical
sponsors and healthcare professionals around the world to quickly
and precisely bring new treatments to patients in need, with an eye
on reducing overall care costs. This is how we are helping to
create a healthier world.
Founded in 2002, based in Sophia-Antipolis, France, with a US
subsidiary in Boston, Median has received the label “Innovative
company” by the BPI and is listed on Euronext Growth market (ISIN:
FR0011049824, ticker: ALMDT). The company is eligible for the
PEA-PME SME equity savings plan setup and has received the label
Pass French Tech Promotion 2017-2018. Median Technologies has been
awarded the 2017 Tech 40 Label, has joined the EnterNext Tech 40
Index and is a winner of the Deloitte Technology Fast 500™ 2017
EMEA program. Median is a member of the Bpifrance Excellence
Network. For more information: www.mediantechnologies.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180213005941/en/
Median TechnologiesMarjorie KoomanVP, Head of Investor
and Media Relations+1 312 282
3923marjorie.kooman@mediantechnologies.comorPress - ALIZE
RPCaroline Carmagnol /Wendy Rigal+ 33 1 44 54 36
66median@alizerp.comorInvestors - ACTIFINGhislaine
Gasparetto+33 1 56 88 11 11ggasparetto@actifin.fr
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Median Technologies (EU:ALMDT)
Historical Stock Chart
From Apr 2023 to Apr 2024